#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: vorasidenib
![Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/02/AFIP-00405558-Glioblastoma-Radiology-e1381685577283-350x250.jpg)
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo ...